KNE:CA:CDX-Kane Biotech Inc. (CAD)

COMMON STOCK | Biotechnology | TSX Venture Exchange

Last Closing

USD 0.13

Change

0.00 (0.00)%

Market Cap

USD 6.60M

Volume

0.03M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Kane Biotech Inc is a biotechnology company engaged in research and development of animal and human health products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NGEN:CA NervGen Pharma Corp

N/A

USD 0.19B
ARCH:CA Arch Biopartners Inc

N/A

USD 0.12B
COV:CA Covalon Technologies Ltd.

N/A

USD 0.08B
MIR:CA MedMira Inc

N/A

USD 0.06B
NRX:CA NurExone Biologic Inc.

N/A

USD 0.04B
TTI:CA Thiogenesis Therapeutics Corp.

N/A

USD 0.03B
GSD:CA Devonian Health Group Inc

N/A

USD 0.02B
SBM:CA Sirona Biochem Corp

N/A

USD 0.02B
HEM:CA Hemostemix Inc

N/A

USD 8.28M
RKV:CA Rakovina Therapeutics Inc

N/A

USD 7.67M

ETFs Containing KNE:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (TSX Venture Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 62.50% 59% D- 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.50% 59% D- 71% C-
Trailing 12 Months  
Capital Gain 73.33% 69% C- 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 73.33% 69% C- 75% C
Trailing 5 Years  
Capital Gain -3.70% 42% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.70% 42% F 49% F
Average Annual (5 Year Horizon)  
Capital Gain -2.86% N/A N/A 46% F
Dividend Return -2.86% N/A N/A 46% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 33.38% N/A N/A 71% C-
Risk Adjusted Return -8.56% N/A N/A 44% F
Market Capitalization 6.60M 61% D- 66% D+

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector